Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430586
Status:
COMPLETED
Last Update Posted:
2011-08-03
First Post:
2007-02-01
Brief Title:
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
Sponsor:
Merz Pharmaceuticals GmbH
Organization:
Merz Pharmaceuticals GmbH
Study Overview
Official Title:
A Prospective Randomized Double-blind Placebo-controlled Multicenter Trial to Determine the Optimal Dose of NT 201 Free of Complexing Proteins in the Treatment of Glabellar Frown Lines
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
NT 201 is a botulinum toxin type A preparation free of complexing proteins ie free of proteins other than the active toxin Injected into the muscle NT 201 causes local weakening to full paralysis depending on the administered dose Botulinum toxin type A is widely used for aesthetic treatment of facial lines This study will determine the optimal dose of NT 201 in the treatment of glabellar frown lines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None